Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 102 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metformin 500 mg bid Clear all
Completed Phase 2 Interventional Results available

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

NCT02656017
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
Kyongtae Ty Bae, M.D., Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Not applicable Interventional Results available

Lifestyle Modification and Metformin Use in the Treatment of HIV

NCT00399360
View directory record Official record
Conditions
HIV Infections, Metabolic Syndrome X
Interventions
Metformin, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)

NCT01329016
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Glyburide, Metformin, Glyburide-Metformin combination
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body

NCT07753252
View directory record Official record
Conditions
Healthy Participants
Interventions
Metformin, Sevabertinib (BAY 2927088)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 3, 2026, 7:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

NCT01638676
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib, Metformin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

NCT00401973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorders
Interventions
olanzapine, amantadine, metformin, zonisamide, Wellness education
Drug · Behavioral
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
National City, California • Canton, Ohio • Johnson City, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2009 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis (NASH) With Metformin

NCT00063232
View directory record Official record
Conditions
Hepatitis
Interventions
Metformin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 3, 2026, 7:29 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canakinumab, Metformin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

NCT02546609
View directory record Official record
Conditions
NAFLD
Interventions
Leu-Met-Sil 0.5, Leu-Met-Sil 1.0, Placebo
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Chino, California • San Diego, California • Wheat Ridge, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

NCT01719003
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

NCT02151461
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Metformin, Mid Metformin, High Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

NCT00670800
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 3, 2026, 7:29 PM EDT
Terminated Phase 4 Interventional

Efficacy of Pharmacotherapy to Enhance Weight Loss Following Sleeve Gastrectomy

NCT03603080
View directory record Official record
Conditions
Obesity
Interventions
Administration of weight loss drug (Metformin or Topiramate)
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)

NCT00063635
View directory record Official record
Conditions
Fatty Liver
Interventions
Metformin, Vitamin E, Matching placebo
Drug · Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL

NCT01750567
View directory record Official record
Conditions
Relapsed Chronic Lymphocytic Leukemia
Interventions
Metformin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

NCT00295633
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
79
States / cities
Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

NCT05657613
View directory record Official record
Conditions
Drug Interactions
Interventions
CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

NCT02338193
View directory record Official record
Conditions
Diabetes Prevention in Women After GDM Who Are at High-risk
Interventions
DAPA/MET XR, DAPA, MET XR
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer

NCT01620593
View directory record Official record
Conditions
Prostate Cancer
Interventions
Placebo, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 3, 2026, 7:29 PM EDT
Recruiting Phase 2 Interventional

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

NCT05660083
View directory record Official record
Conditions
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
Interventions
L-NMMA
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 1 Interventional

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

NCT01546558
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Metabolic and Neuro-Endocrine Effect of Treating PCOS in Adolescents

NCT03981861
View directory record Official record
Conditions
PCOS
Interventions
Metformin and Spironolactone
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 3, 2026, 7:29 PM EDT
Terminated Phase 1 Interventional Results available

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

NCT01525225
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 3, 2026, 7:29 PM EDT